I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

III currently has a forward P/E ratio of 17.03, while EFX has a forward P/E of 35.65. We also note that III has a PEG ratio of 1.06. This figure is similar to the commonly-used P/E ratio, with the ...

In recent trading, shares of Equifax Inc (Symbol: EFX) have crossed above the average analyst 12-month target price of $205.75, changing hands for $209.53/share. When a stock reaches the target an ...